We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Immunotherapy of Malignant Disease

Sigmond H. Nadler, MD; George E. Moore, MD, PhD
Arch Surg. 1969;99(3):376-381. doi:10.1001/archsurg.1969.01340150084016.
Text Size: A A A
Published online


The importance of host resistance and immunological factors in influencing the growth of tumors has been suspected for over 50 years.1 A great deal of experimental evidence has accumulated in the past two decades to support this thesis, and further studies in the immunologic field are now warranted on the basis of this evidence.

The mechanisms by which host cells inhibit cancer growth or destroy cancer cells is not completely understood. Much of the early experimental work was concerned with attempts to demonstrate circulating antibodies against malignant tissues, identify specific tumor antigens, and develop effective cancer vaccines. In 1953, Foley2 demonstrated specific antigenicity in a class of experimentally induced tumors induced by methylcholanthrene in syngeneic mice. He demonstrated that the removal of a growing transplant of an induced tumor was followed by resistance to subsequent challenge with the same tumor. These experiments have been confirmed many times and


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.